Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer

World Journal of Gastroenterology

Volumn 20, Issue 23, 2014, Pages 7137-7151

  Sabatino, Lina ^a   Pancione, Massimo ^a   Votino, Carolina ^a   Colangelo, Tommaso ^a   Lupo, Angelo ^a   Novellino, Ettore ^b   Lavecchia, Antonio ^b   Colantuoni, Vittorio ^a  

^a UNIVERSITY OF SANNIO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Colorectal cancer; Genomic instability; Peroxisome proliferator activated receptor ligands; Peroxisome proliferator activated receptor ; Wnt catenin pathway

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CAPSAICIN; CELECOXIB; CELL AND TISSUE EXTRACTS; CGP 049090; CURCUMIN; CYCLIN D1; DICLOFENAC; FRIZZLED PROTEIN; HERMES ANTIGEN; INDOMETACIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PKF 115 584; PKF 118 744; PKF 222 310; PKF 222 815; QUERCETIN; RESVERATROL; RETINOIC ACID DERIVATIVE; RETINOID X RECEPTOR; SULINDAC; SURVIVIN; THYMOQUINONE; UNCLASSIFIED DRUG; UVOMORULIN; ANTINEOPLASTIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACHAETE SCUTE COMPLEX; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FAMILIAL COLON POLYPOSIS; GENE MUTATION; HUMAN; MOLECULAR INTERACTION; PATHOGENESIS; WNT SIGNALING PATHWAY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PPAR GAMMA; WNT SIGNALING PATHWAY;

EID: 84902665808     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i23.7137     Document Type: Article

References (116)

1. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345-2357 [PMID: 22612596 DOI: 10.1056/NEJMoa1114635]
2. Centelles JJ. General aspects of colorectal cancer. ISRN Oncol 2012; 2012: 139268 [PMID: 23209942 DOI: 10.5402/2012/139268]
3. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507 [PMID: 21090969 DOI: 10.1146/ annurevpathol-011110-130235]
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767 [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-I]
5. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-237 [PMID: 1528264 DOI: 10.1038/359235]
6. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int 2012; 2012: 509348 [PMID: 22888469 DOI: 10.1155/2012/509348]
7. Issa JP. Colon cancer: it's CIN or CIMP. Clin Cancer Res 2008; 14: 5939-5940 [PMID: 18829469 DOI: 10.1158/1078-0432. CCR-08-1596]
8. De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, Rodermond H, van der Heijden M, van Noesel CJ, Tuynman JB, Dekker E, Markowetz F, Medema JP, Vermeulen L. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-618 [PMID: 23584090]
9. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-625 [PMID: 23584089 DOI: 10.1038/nm.3175]
10. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26 [PMID: 19619488 DOI: 10.1016/j.devcel.2009.06.016]
11. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
12. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688 [PMID: 10529898]
13. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4: 61-70 [PMID: 14708026 DOI: 10.1038/ nrc1254]
14. Pancione M, Sabatino L, Fucci A, Carafa V, Nebbioso A, Forte N, Febbraro A, Parente D, Ambrosino C, Normanno N, Altucci L, Colantuoni V. Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One 2010; 5: e14229 [PMID: 21151932 DOI: 10.1371/journal. pone.0014229]
15. Sabatino L, Fucci A, Pancione M, Carafa V, Nebbioso A, Pistore C, Babbio F, Votino C, Laudanna C, Ceccarelli M, Altucci L, Bonapace IM, Colantuoni V. UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene 2012; 31: 5061-5072 [PMID: 22286757 DOI: 10.1038/onc.2012.3]
16. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 2009; 136: 1242-1250 [PMID: 19186181 DOI: 10.1053/ j.gastro.2008.12048]
17. Clevers H. The intestinal crypt, a prototype stem cell compartment. Cell 2013; 154: 274-284 [PMID: 23870119 DOI: 10.1016/j.cell.2013.07.004]
18. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H. The Intestinal Wnt/ TCF Signature. Gastroenterology 2007; 132: 628-632 [PMID: 17320548 DOI: 10.1053/j.gastro.2006.08.039]
19. Fearon ER. PARsing the phrase "all in for Axin"-Wnt pathway targets in cancer. Cancer Cell 2009; 16: 366-368 [PMID: 19878868 DOI: 10.1016/j.ccr.2009.10.007]
20. Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, Ge N, Hutchins GG, Pine JK, Quirke P, Koeppen H, Jubb AM. In situ validation of an intestinal stem cell signature in colorectal cancer. Gut 2013; 62: 1012-1023 [PMID: 22637696 DOI: 10.1136/gutjnl-2011-301195]
21. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L. The Hippo pathway regulates Wnt/ beta-catenin signaling. Dev Cell 2010; 18: 579-591 [PMID: 20412773 DOI: 10.1016/j.devcel.2010.03.007]
22. Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling. EMBO J 2012; 31: 1109-1122 [PMID: 22234184 DOI: 10.1038/emboj.2011.487]
23. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480 [PMID: 17081971 DOI: 10.1016/j.cell.2006.10.018]
24. Verheyen EM, Gottardi CJ. Regulation of Wnt/beta-catenin signaling by protein kinases. Dev Dyn 2010; 239: 34-44 [PMID: 19623618 DOI: 10.1002/dvdy.22019]
25. Liu J, Wang H, Zuo Y, Farmer SR. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol 2006; 26: 5827-5837 [PMID: 16847334 DOI: 10.1128/MCB.00441-06]
26. Willert K, Nusse R. Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 1998; 8: 95-102 [PMID: 9529612 DOI: 10.1016/S0959-437x(98)80068-3]
27. Huber AH, Nelson WJ, Weis WI. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell 1997; 90: 871-882 [PMID: 9298899 DOI: 10.1016/S0092-8674(00)80352-9]
28. Graham TA, Weaver C, Mao F, Kimelman D, Xu W. Crystal structure of a beta-catenin/Tcf complex. Cell 2000; 103: 885-896 [PMID: 11136974 DOI: 10.1016/S0092-8674(00)00192-6]
29. Huber AH, Weis WI. The structure of the beta-catenin/ E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001; 105: 391-402 [PMID: 11348595 DOI: 10.1016/S0092-8674(01)00330-0]
30. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851 [PMID: 10921899 DOI: 10.1101/gad.14.15.1837]
31. Chen Z, He X, Jia M, Liu Y, Qu D, Wu D, Wu P, Ni C, Zhang Z, Ye J, Xu J, Huang J. β-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis. PLoS One 2013; 8: e63854 [PMID: 23717499 DOI: 10.1371/journal.pone.0063854]
32. Rao TP, Kühl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 2010; 106: 1798-1806 [PMID: 20576942]
33. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherincatenin adhesion system in signaling and cancer. J Clin Invest 2002; 109: 987-991 [PMID: 11956233 DOI: 10.1172/ JCI200215429]
34. Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. β-catenin/TCF4 complex induces the epithelialto-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 2011; 108: 19204-19209 [PMID: 22080605 DOI: 10.1073/pnas.1108977108]
35. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123: 993-999 [PMID: 16360030 DOI: 10.1016/ j.cell.2005.11.026]
36. Sabatino L, Fucci A, Pancione M, Colantuoni V. PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis. PPAR Res 2012; 2012: 687492 [PMID: 22848209 DOI: 10.1155/2012/687492]
37. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006; 45: 120-159 [PMID: 16476485 DOI: 10.1016/jplipres.2005.12.002]
38. Wang D, Dubois RN. Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res 2008; 2008: 931074 [PMID: 18551185 DOI: 10.1155/2008/931074]
39. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, Sasatomi K, Kimura R, Hashimoto O, Ueno T, Yano H, Kojiro M, Sata M. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001; 33: 1087-1097 [PMID: 11343236]
40. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000; 60: 5558-5564 [PMID: 11034103]
41. Zhang W, Wu N, Li Z, Wang L, Jin J, Zha XL. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther 2006; 5: 1008-1014 [PMID: 16775433 DOI: 10.4161/cbt.5.8.2887]
42. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC, Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NFkappaB in human colon cancer. Life Sci 2002; 70: 2631-2646 [PMID: 12269390]
43. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110: 923-932 [PMID: 12370270 DOI: 10.1172/JCI200215634]
44. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759-763 [PMID: 16127449 DOI: 10.1038/nature03988]
45. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010; 9: 3221-3232 [PMID: 21159608 DOI: 10.1158/1535-7163.MCT-10-0570]
46. Tachibana K, Yamasaki D, Ishimoto K, Doi T. The Role of PPARs in Cancer. PPAR Res 2008; 2008: 102737 [PMID: 18584037 DOI: 10.1155/2008/102737]
47. Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M, Pilarsky C. Peroxisome proliferatoractivated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 2006; 12: 6444-6451 [PMID: 17085658 DOI: 10.1158/1078-0432.CCR-06-0834]
48. Lee JJ, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012; 31: 3818-3825 [PMID: 22120719 DOI: 10.1038/onc.2011.543]
49. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-1061 [PMID: 9734400 DOI: 10.1038/2042]
50. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-1057 [PMID: 9734399 DOI: 10.1038/2036]
51. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apcdeficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003; 63: 6090-6095 [PMID: 14522940]
52. Niho N, Takahashi M, Shoji Y, Takeuchi Y, Matsubara S, Sugimura T, Wakabayashi K. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci 2003; 94: 960-964 [PMID: 14611672 DOI: 10.1111/j.1349-7006.2003]
53. McAlpine CA, Barak Y, Matise I, Cormier RT. Intestinalspecific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int J Cancer 2006; 119: 2339-2346 [PMID: 16858678]
54. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003; 124: 361-367 [PMID: 12557142 DOI: 10.1053/gast.2003.50067]
55. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001; 61: 6213-6218 [PMID: 11507074]
56. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R, Gonzalez FJ, Spiegelman BM. APCdependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002; 99: 13771-13776 [PMID: 12370429]
57. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217 [PMID: 15766659 DOI: 10.1016/j.ccr.2005.02.013]
58. Danese S, Malesci A, Vetrano S. Colitis-associated cancer: the dark side of inflammatory bowel disease. Gut 2011; 60: 1609-1610 [PMID: 21997561 DOI: 10.1136/gutjnl-2011-300953]
59. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Lossof-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3: 799-804 [PMID: 10394368 DOI: 10.1016/S1097-2765(01)80012-5]
60. Burgermeister E, Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 2007; 6: 1539-1548 [PMID: 17611413 DOI: 10.4161/cc.6.13.4453]
61. Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, Febbraro A, Colantuoni V. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 2009; 40: 714-725 [PMID: 19121846 DOI: 10.1016/j.humpath.2008.08.019]
62. Dai Y, Wang WH. Peroxisome proliferator-activated receptor γ and colorectal cancer. World J Gastrointest Oncol 2010; 2: 159-164 [PMID: 21160824 DOI: 10.4251/wjgo.w2i3.159]
63. Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente D, Forte N, Colantuoni V. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia 2013; 15: 1086-1099 [PMID: 24027433 DOI: 10.1593/neo.13998]
64. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005; 26: 898-915 [PMID: 16126938 DOI: 10.1210/er.2003-0034]
65. Botrugno OA, Fayard E, Annicotte JS, Haby C, Brennan T, Wendling O, Tanaka T, Kodama T, Thomas W, Auwerx J, Schoonjans K. Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell 2004; 15: 499-509 [PMID: 15327767 DOI: 10.1016/j.molcel.2004.07.009]
66. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277: 11336-11344 [PMID: 11792709 DOI: 10.1074/ jbc.M11196220]
67. Jansson EA, Are A, Greicius G, Kuo IC, Kelly D, Arulampalam V, Pettersson S. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci USA 2005; 102: 1460-1465 [PMID: 15665104 DOI: 10.1073/pnas.0405928102]
68. Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor gamma and betacatenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of betacatenin inhibits expression of a subset of adipogenic genes. J Biol Chem 2004; 279: 45020-45027 [PMID: 15308623 DOI: 10.1074/jbc.M40705020]
69. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-780 [PMID: 14570043 DOI: 10.1038/nrc1189]
70. Teiten MH, Gaascht F, Dicato M, Diederich M. Targeting the wingless signaling pathway with natural compounds as chemopreventive or chemotherapeutic agents. Curr Pharm Biotechnol 2012; 13: 245-254 [PMID: 21466435 DOI: 10.2174/1 38920112798868593]
71. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26 [PMID: 23258168 DOI: 10.1038/nrc3419]
72. Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 2002; 23: 107-114 [PMID: 11756231 DOI: 10.1093/carcin/23.1.107]
73. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 2001; 20: 645-653 [PMID: 11313997]
74. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ. Sulindac metabolites induce caspase-and proteasome-dependent degradation of betacatenin protein in human colon cancer cells. Mol Cancer Ther 2003; 2: 885-892 [PMID: 14555707]
75. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000; 60: 3338-3342 [PMID: 10910034]
76. Dihlmann S, Klein S, Doeberitz MV. Reduction of betacatenin/ T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003; 2: 509-516 [PMID: 12813129]
77. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410 [PMID: 9013583 DOI: 10.1074/jbc.272.6.3406]
78. Shah S, Hecht A, Pestell R, Byers SW. Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem 2003; 278: 48137-48145 [PMID: 12972427]
79. Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Muñoz A. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001; 154: 369-387 [PMID: 11470825 DOI: 10.1083/jcb.200102028]
80. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5: 91-102 [PMID: 14749129 DOI: 10.1016/S1535-6108(03)00334-9]
81. Hope C, Planutis K, Planutiene M, Moyer MP, Johal KS, Woo J, Santoso C, Hanson JA, Holcombe RF. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol Nutr Food Res 2008; 52 Suppl 1: S52-S61 [PMID: 18504708 DOI: 10.1002/mnfr.200700448]
82. Lu D, Carson DA. Repression of beta-catenin signaling by PPAR gamma ligands. Eur J Pharmacol 2010; 636: 198-202 [PMID: 20303941 DOI: 10.1016/j.ejphar.2010.03.010]
83. Burris TP, Busby SA, Griffin PR. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 2012; 19: 51-59 [PMID: 22284354 DOI: 10.1016/j.chembiol.2011.12.011]
84. Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 2009; 15: 2-8 [PMID: 19118026 DOI: 10.1158/1078-0432.ccr-08-0326]
85. Menendez-Gutierrez MP, Roszer T, Ricote M. Biology and therapeutic applications of peroxisome proliferator-activated receptors. Curr Top Med Chem 2012; 12: 548-584 [PMID: 22242855 DOI: 10.2174/156802612799436669]
86. Puhl AC, Bernardes A, Silveira RL, Yuan J, Campos JL, Saidemberg DM, Palma MS, Cvoro A, Ayers SD, Webb P, Reinach PS, Skaf MS, Polikarpov I. Mode of peroxisome proliferator-activated receptor γ activation by luteolin. Mol Pharmacol 2012; 81: 788-799 [PMID: 22391103 DOI: 10.1124/ mol.111.076216]
87. Pochetti G, Mitro N, Lavecchia A, Gilardi F, Besker N, Scotti E, Aschi M, Re N, Fracchiolla G, Laghezza A, Tortorella P, Montanari R, Novellino E, Mazza F, Crestani M, Loiodice F. Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and sitedirected mutagenesis. J Med Chem 2010; 53: 4354-4366 [PMID: 20462215 DOI: 10.1021/jm9013899]
88. Laghezza A, Pochetti G, Lavecchia A, Fracchiolla G, Faliti S, Piemontese L, Di Giovanni C, Iacobazzi V, Infantino V, Montanari R, Capelli D, Tortorella P, Loiodice F. New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression. J Med Chem 2013; 56: 60-72 [PMID: 23171045 DOI: 10.1021/ jm301018z]
89. Zurlo D, Leone C, Assante G, Salzano S, Renzone G, Scaloni A, Foresta C, Colantuoni V, Lupo A. Cladosporol a stimulates G1-phase arrest of the cell cycle by up-regulation of p21(waf1/cip1) expression in human colon carcinoma HT-29 cells. Mol Carcinog 2013; 52: 1-17 [PMID: 22025467 DOI: 10.1002/mc.20872]
90. Fracchiolla G, Laghezza A, Piemontese L, Carbonara G, Lavecchia A, Tortorella P, Crestani M, Novellino E, Loiodice F. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity. ChemMed-Chem 2007; 2: 641-654 [PMID: 17357171 DOI: 10.1002/ cmdc.200600307]
91. Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 2005; 328: 227-234 [PMID: 15670774 DOI: 10.1016/ j.bbrc.2004.12.151]
92. Shan BE, Wang MX, Li RQ. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest 2009; 27: 604-612 [PMID: 19440933 DOI: 10.1080/07357900802337191]
93. Lee H, Bae S, Yoon Y. The anti-adipogenic effects of (-)epigallocatechin gallate are dependent on the WNT/β-catenin pathway. J Nutr Biochem 2013; 24: 1232-1240 [PMID: 23318137 DOI: 10.1016/j.jnutbio.2012.09.007]
94. Dashwood WM, Orner GA, Dashwood RH. Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H(2)O(2) at physiologically relevant EGCG concentrations. Biochem Biophys Res Commun 2002; 296: 584-588 [PMID: 12176021 DOI: 10.1016/S0006-291X(02)00914-2]
95. Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, Yee AS. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J Biol Chem 2006; 281: 10865-10875 [PMID: 16495219 DOI: 10.1016/ j.febslet.2005.04.013]
96. Park CH, Hahm ER, Park S, Kim HK, Yang CH. The inhibitory mechanism of curcumin and its derivative against betacatenin/ Tcf signaling. FEBS Lett 2005; 579: 2965-2971 [PMID: 15893313]
97. Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-cateninmediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002; 21: 8414-8427 [PMID: 12466962 DOI: 10.1038/ sj.onc.1205947]
98. Chen HJ, Hsu LS, Shia YT, Lin MW, Lin CM. The β-catenin/ TCF complex as a novel target of resveratrol in the Wnt/ β-catenin signaling pathway. Biochem Pharmacol 2012; 84: 1143-1153 [PMID: 22935447 DOI: 10.1016/j.bcp.2012.08.01]
99. Li H, Wu WK, Li ZJ, Chan KM, Wong CC, Ye CG, Yu L, Sung JJ, Cho CH, Wang M. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Br J Pharmacol 2010; 160: 1352-1361 [PMID: 20590626 DOI: 10.1111/j.1476-5381.2010.00785.x]
100. Jingushi K, Takahashi-Yanaga F, Yoshihara T, Shiraishi F, Watanabe Y, Hirata M, Morimoto S, Sasaguri T. DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines. Biochem Pharmacol 2012; 83: 47-56 [PMID: 22005519 DOI: 10.1016/ j.bcp.2011.10.001]
101. Takahashi-Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y, Morimoto S, Sasaguri T. Involvement of GSK-3beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J Biol Chem 2006; 281: 38489-38497 [PMID: 17046823 DOI: 10.1074/ jbc.M605205200]
102. Lee SH, Richardson RL, Dashwood RH, Baek SJ. Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells. J Nutr Biochem 2012; 23: 646-655 [PMID: 21764279 DOI: 10.1016/j.jnutbio.2011.03.009]
103. Lee SH, Krisanapun C, Baek SJ. NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 2010; 31: 719-728 [PMID: 20110283 DOI: 10.1093/carcin/bgq016]
104. Lang M, Borgmann M, Oberhuber G, Evstatiev R, Jimenez K, Dammann KW, Jambrich M, Khare V, Campregher C, Ristl R, Gasche C. Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling. Mol Cancer 2013; 12: 41 [PMID: 23668310 DOI: 10.1186/1476-4598-12-41]
105. Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol 2012; 83: 443-451 [PMID: 22005518 DOI: 10.1016/ j.bcp.2011.09.029]
106. Dillard AC, Lane MA. Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines. Mol Carcinog 2007; 46: 315-329 [PMID: 17219422 DOI: 10.1002/ mc.20280]
107. Jiang Y, Prunier C, Howe PH. The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin. Oncogene 2008; 27: 1865-1875 [PMID: 17922036 DOI: 10.1038/sj.onc.121082]
108. Pendás-Franco N, Aguilera O, Pereira F, González-Sancho JM, Muñoz A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res 2008; 28: 2613-2623 [PMID: 19035286]
109. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596 [PMID: 1669840 DOI: 10.1056/NEJM199112053252301]
110. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002; 3: 166-174 [PMID: 11902503 DOI: 10.1016/S1470-2045(02)00680-0]
111. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266 [PMID: 11854387 DOI: 10.1093/jnci/94.4.252]
112. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890 [PMID: 12621132 DOI: 10.1056/NEJMoa021633]
113. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899 [PMID: 12621133 DOI: 10.1056/NEJMoa021735]
114. Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB, Abadi AH, Moyer MP, Grizzle WE, Chang WC, Clapper ML, Piazza GA. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/ PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther 2013; 12: 1848-1859 [PMID: 23804703 DOI: 10.1158/1535-7163.MCT-13-0048]
115. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, Pals ST. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004; 90: 224-229 [PMID: 14710233]
116. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 2007; 73: 1318-1329 [PMID: 17270149 DOI: 10.1016/j.bcp.2006.12.033]